News & Events about Sol Gel Technologies Ltd.
Globe Newswire
6 months ago
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gels pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with ...
Globe Newswire
8 months ago
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a dermatology company with FDA approvals for EPSOLAY and TWYNEO, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced ...
Globe Newswire
8 months ago
Patidegib, an Orphan Drug candidate, broadens Sol-Gels pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to initiate in the second half of 2023, with results expected by the end of ...
Globe Newswire
10 months ago
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gels cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology ...
Ticker Report
11 months ago
Jefferies Financial Group began coverage on shares of Sol-Gel Technologies (NASDAQ:SLGL Get Rating) in a report issued on Friday morning, The Fly reports. The brokerage issued a hold rating and a $5.50 price objective on the stock. Separately, HC Wainwright increased their price objective on...